BLA 020725 · Abbvie
Creon
Pancrelipase (Amylase, Lipase, Protease) · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Apr 30, 2009
Approved uses
4
Original approval plus efficacy supplements
Registered trials
n/a
n/a Phase 3, n/a recruiting
FAERS reports
38,797
28,976 serious, 3,888 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 28, 2024.
CREON ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. CREON is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.
Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 12, 2011 Supplement 8 · Efficacy Label
- Jul 29, 2010 Supplement 6 · Efficacy LetterLabel
- Apr 30, 2010 Supplement 3 · Efficacy LabelLetter
- Apr 30, 2009 Original approval · Type 7 - Drug Already Marketed without Approved NDA · priority review LetterPediatric Medical ReviewPediatric Clinical Pharmacology Review
5 products under this application
- CREON · PANCRELIPASE (AMYLASE 15,000USP UNITS; LIPASE 3,000USP UNITS; PROTEASE) 9,500USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- CREON · PANCRELIPASE (AMYLASE 60,000USP UNITS; LIPASE 12,000USP UNITS; PROTEASE) 38,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- CREON · PANCRELIPASE (AMYLASE 180,000USP UNITS; LIPASE 36,000USP UNITS; PROTEASE) 114,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- CREON · PANCRELIPASE (AMYLASE 120,000USP UNITS; LIPASE 24,000USP UNITS; PROTEASE) 76,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- CREON · PANCRELIPASE (AMYLASE 30,000USP UNITS; LIPASE 6,000USP UNITS; PROTEASE) 19,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea3,834
- death2,040
- nausea1,890
- weight decreased1,856
- fatigue1,660
- abdominal pain1,572
- vomiting1,475
- pain1,338
- abdominal pain upper1,311
- pancreatic carcinoma1,295
- infective pulmonary exacerbation of cystic fibrosis1,238
- drug ineffective1,209
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 105 |
| 2005 | 94 |
| 2006 | 99 |
| 2007 | 86 |
| 2008 | 127 |
| 2009 | 191 |
| 2010 | 290 |
| 2011 | 380 |
| 2012 | 498 |
| 2013 | 686 |
| 2014 | 958 |
| 2015 | 1,365 |
| 2016 | 1,772 |
| 2017 | 1,795 |
| 2018 | 2,451 |
| 2019 | 3,620 |
| 2020 | 3,401 |
| 2021 | 2,446 |
| 2022 | 2,749 |
| 2023 | 2,591 |
| 2024 | 3,627 |
| 2025 | 5,350 |
| 2026 | 4,115 |
Recalls
2 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Sep 15, 2014 · Class II · Terminated
Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Creon (Lipase/Protease/Amylase)
2024 spending
$1.49B
Beneficiaries
185,261
775,061 claims
Per beneficiary
$8,061
$8.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $960,235,542 |
| 2021 | $1,111,601,793 |
| 2022 | $1,310,801,528 |
| 2023 | $1,466,866,603 |
| 2024 | $1,493,447,100 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of enzyme supplementation after surgery for chronic pancreatitis.
Van Hoozen CM, Peeke PG, Taubeneck M, et al. · Pancreas 1997 · Clinical Trial, Randomized Controlled Trial
- Stimulating effect of pancreatic-like enzymes on the development of the gastrointestinal tract in piglets.
Supecka M, Woliski J, Prykhodko O, et al. · J Anim Sci 2012 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Pancreatic enzyme replacement therapy for young cystic fibrosis patients.
Munck A, Duhamel JF, Lamireau T, et al. · J Cyst Fibros 2009 · Multicenter Study, Randomized Controlled Trial
- Health effects of ultraviolet irradiation in asthmatic children's homes.
Bernstein JA, Bobbitt RC, Levin L, et al. · J Asthma 2006 · Comparative Study, Randomized Controlled Trial
- Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients.
Carroccio A, Guarino A, Zuin G, et al. · Aliment Pharmacol Ther 2001 · Clinical Trial, Research Support, Non-U.S. Gov't
- Treatment of pancreatic insufficiency using pancreatic extract in patients with advanced pancreatic cancer: a pilot study (PICNIC).
Zdenkowski N, Radvan G, Pugliese L, et al. · Support Care Cancer 2017 · Randomized Controlled Trial
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.